申请人:Sumitomo Pharmaceuticals Company, Limited
公开号:US05814654A1
公开(公告)日:1998-09-29
A substituted guanidine derivative represented by the general formula: ##STR1## is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton (Na.sup.+ /H.sup.+) exchange transport system, for example, hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes mellitus, organ disorders associated with ischemia or ischemic reperfusion, cerebroischemic disorders, diseases caused by excessive cell proliferation, or diseases caused by endothelial cell injury.
一种代表一般式的取代胍衍生物:## STR1 ## 可用作治疗或预防因钠/质子(Na.sup.+ / H.sup.+)交换转运系统加速而引起的疾病的药物,例如高血压,心律失常,心绞痛,心脏肥大,糖尿病,与缺血或缺血再灌注相关的器官疾病,脑缺血性疾病,由过度细胞增殖引起的疾病或由内皮细胞损伤引起的疾病。